Ellagic Acid as a Novel YTHDF Inhibitor Triggers Tumor-Suppressive in Triple-Negative Breast Cancer II

The m⁶A reader proteins YTHDF1–3 are key post-transcriptional regulators of m⁶A-modified transcripts in mammalian cells, and have emerged as critical contributors to the pathogenesis of triple-negative breast cancer (TNBC). Given their role in promoting tumorigenic phenotypes, YTHDF1–3 represent promising therapeutic targets. In this study, we identified ellagic acid (EA), a natural small molecule, as a pan-inhibitor of YTHDF proteins. To investigate the translational consequences of YTHDF inhibition, we performed ribosome profiling (Ribo-seq) to assess the global impact of EA on mRNA translation in TNBC cells.